Drug Search Results
More Filters [+]

Oxelumab

Alternative Names: oxelumab, RO4989991, RO 4989991, RO-4989991
Latest Update: 2016-11-02
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: OX40 Antagonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oxelumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Asthma, Allergic|Rhinitis, Allergic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PP22831

P1

Completed

Rhinitis, Allergic|Asthma, Allergic

2011-02-01

Recent News Events

Date

Type

Title